Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: From 10-K--preferred stock (Note in bold)

Mea maxima culpa in trying to influence shareholders into thinking about what has been posted and what has been avoided.

From the 10-K it would appear that the BoD have got it under control: a core focus on reducing expenditure and developing PDSG in line with revenue; written off/sold extraneous divisions with the benefit of tax loss offsets on future profits(effectively making the much maligned M&A investments cost neutral); and commenced litigation against TPL/Alliacense.

The only specific suggestion that I therefore have is NOT to pay any dividends until such time that there are sufficient funds to enable both concurrent M&A activity and dividend payments - I previously suggested $100 million in reserves as the optimum.

$100 million would give an approximate NAV of 25 cents which would no doubt place a bottom on the share price.

Will you be now answering the questions asked of you by others, or continue to avoid doing so?

"What's a shareholder to think?"

.

.

.

Be well

Share
New Message
Please login to post a reply